Reproducibility Study of Overactive Bladder Symptom Score [OABSS]
RESORT-1
Reproducibility Study of OABSS and Its Response to Treatment in Indonesia - Part 1: Reproducibility -
1 other identifier
observational
50
1 country
3
Brief Summary
The purpose of this study is to evaluate its reproducibility of overactive bladder symptom score (OABSS) and to evaluate its correlation to other measures of OAB symptoms.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2009
Shorter than P25 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2009
CompletedFirst Submitted
Initial submission to the registry
May 11, 2010
CompletedFirst Posted
Study publicly available on registry
May 13, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2010
CompletedAugust 24, 2010
August 1, 2010
11 months
May 11, 2010
August 23, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
OABSS
Weeks 0 and 2
Secondary Outcomes (3)
International Prostate Symptom Score (IPSS)
Weeks 0 and 2
Quality of Life (QOL) score
Weeks 0 and 2
Patient Perception of Bladder Condition (PPBC)
Weeks 0 and 2
Eligibility Criteria
Symptomatic OAB patients having urgency episodes
You may qualify if:
- Symptoms OAB for 3 months or longer
- At least 1 urgency episode in last 3 days
- Symptoms of OAB as verified by 3-day micturition diary prior to Visit 1, defined by:
- Number of micturition per day ≥8
- Number of urgency episodes in 3 days ≥1
You may not qualify if:
- Significant stress incontinence or mixed stress/urge incontinence
- Subjects with indwelling catheters or practicing intermittent self-catheterization
- Symptomatic urinary tract infection, chronic inflammation
- Diabetic neuropathy
- Drug or non-drug treatment for OAB was started, quitted or changed in 4 weeks
- Participation in any clinical trial in 30 days
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Astellas Pharma Inclead
- Astellas Pharma Indonesia Inc.collaborator
Study Sites (3)
Unknown Facility
Bandung, Indonesia
Unknown Facility
Jakarta, Indonesia
Unknown Facility
Surabaya, Indonesia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Use Central Contact
Astellas Pharma Indonesia
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
May 11, 2010
First Posted
May 13, 2010
Study Start
September 1, 2009
Primary Completion
August 1, 2010
Study Completion
August 1, 2010
Last Updated
August 24, 2010
Record last verified: 2010-08